

George F Wohlford

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5110407/publications.pdf>

Version: 2024-02-01

28
papers

963
citations

623734

14
h-index

501196

28
g-index

29
all docs

29
docs citations

29
times ranked

1335
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of Cardiorespiratory Fitness in Black or African American Versus Caucasian Patients With Heart Failure. <i>Journal of Cardiopulmonary Rehabilitation and Prevention</i> , 2022, 42, 39-44.	2.1	6
2	Interleukin-1 blockade with anakinra and heart failure following ST-segment elevation myocardial infarction: results from a pooled analysis of the VCUART clinical trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 503-510.	3.0	37
3	Acute Effects of Liothyronine Administration on Cardiovascular System and Energy Metabolism in Healthy Volunteers. <i>Frontiers in Endocrinology</i> , 2022, 13, 843539.	3.5	2
4	Stenting techniques for coronary bifurcation lesions: Evidence from a network meta-analysis of randomized clinical trials. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, E306-E318.	1.7	13
5	Effect of Extracorporeal Membrane Oxygenation Support on the Plasma Levels of Commonly Utilized Catecholamines. <i>ASAIO Journal</i> , 2021, 67, e204-e206.	1.6	0
6	A phase 1 clinical trial of SP16, a first-in-class anti-inflammatory LRP1 agonist, in healthy volunteers. <i>PLoS ONE</i> , 2021, 16, e0247357.	2.5	7
7	Preservation of Cardiac Reserve and Cardiorespiratory Fitness in Patients With Acute De Novo Versus Acute on Chronic Heart Failure With Reduced Ejection Fraction. <i>American Journal of Cardiology</i> , 2021, 158, 74-80.	1.6	3
8	Clinical trial enrollment at a rural satellite hospital during COVID-19 pandemic. <i>Journal of Clinical and Translational Science</i> , 2021, 5, e136.	0.6	6
9	Phase 1B, Randomized, Double-Blinded, Dose Escalation, Single-Center, Repeat Dose Safety and Pharmacodynamics Study of the Oral NLRP3 Inhibitor Dapansutrile in Subjects With NYHA II-III Systolic Heart Failure. <i>Journal of Cardiovascular Pharmacology</i> , 2021, 77, 49-60.	1.9	65
10	Determinants of Cardiorespiratory Fitness in Patients with Heart Failure Across a Wide Range of Ejection Fractions. <i>American Journal of Cardiology</i> , 2020, 125, 76-81.	1.6	10
11	Management of Acute and Recurrent Pericarditis. <i>Journal of the American College of Cardiology</i> , 2020, 75, 76-92.	2.8	197
12	Sacubitril-Valsartan for the Treatment of Heart Failure. <i>Journal of Cardiovascular Pharmacology</i> , 2020, 75, 105-107.	1.9	4
13	Inflammation and Hypertension. <i>Hypertension</i> , 2020, 75, 297-298.	2.7	15
14	Acute Effects of Interleukin-1 Blockade Using Anakinra in Patients With Acute Pericarditis. <i>Journal of Cardiovascular Pharmacology</i> , 2020, 76, 50-52.	1.9	20
15	Interleukin-1 Blockade Inhibits the Acute Inflammatory Response in Patients With ST-Segment Elevation Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2020, 9, e014941.	3.7	150
16	COLCOT and CANTOS: piecing together the puzzle of inflammation and cardiovascular events. <i>Minerva Cardioangiologica</i> , 2020, 68, 5-8.	1.2	5
17	Pharmacokinetics of L-Triiodothyronine in Patients Undergoing Thyroid Hormone Therapy Withdrawal. <i>Thyroid</i> , 2019, 29, 1371-1379.	4.5	21
18	Potential role for interleukin-1 in the cardio-renal syndrome. <i>European Journal of Heart Failure</i> , 2019, 21, 385-386.	7.1	9

#	ARTICLE	IF	CITATIONS
19	Metabolic modulation predicts heart failure tests performance. PLoS ONE, 2019, 14, e0218153.	2.5	20
20	Recent Updates on the Use of PCSK9 Inhibitors in Patients with Atherosclerotic Cardiovascular Disease. Current Atherosclerosis Reports, 2019, 21, 16.	4.8	16
21	Alirocumab in Acute Myocardial Infarction: Results From the Virginia Commonwealth University Alirocumab Response Trial (VCU-AlirocRT). Journal of Cardiovascular Pharmacology, 2019, 74, 266-269.	1.9	24
22	In-Hospital Initiation of Sacubitril/Valsartan: A New PARADIGM for Acute Decompensated Heart Failure?. Journal of Cardiovascular Pharmacology, 2019, 74, 1-3.	1.9	5
23	Effect of intensive blood pressure control in patients with type 2 diabetes mellitus over 9 years of follow-up: A subgroup analysis of high-risk ACCORDION trial participants. Diabetes, Obesity and Metabolism, 2018, 20, 1499-1502.	4.4	36
24	C-Reactive Protein and N-Terminal Pro-brain Natriuretic Peptide Levels Correlate With Impaired Cardiorespiratory Fitness in Patients With Heart Failure Across a Wide Range of Ejection Fraction. Frontiers in Cardiovascular Medicine, 2018, 5, 178.	2.4	21
25	IL-1 Blockade in Patients With Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2018, 11, e005036.	3.9	129
26	Response to Comment on Buckley et al. Intensive Versus Standard Blood Pressure Control in SPRINT-Eligible Participants of ACCORD-BP. Diabetes Care 2017;40:1733-1738. Diabetes Care, 2018, 41, e86-e87.	8.6	2
27	Rationale and design of the Virginia Commonwealth University Anakinra Remodeling Trial (VCU-ART3): A randomized, placebo-controlled, double-blind, multicenter study. Clinical Cardiology, 2018, 41, 1004-1008.	1.8	41
28	Intensive Versus Standard Blood Pressure Control in SPRINT-Eligible Participants of ACCORD-BP. Diabetes Care, 2017, 40, 1733-1738.	8.6	98